IL17A and colitis: Compared to untreated controls, treatment with antimiR-31 in both colitis models improved intestinal histology and weight recovery, and showed a marked decrease in IFN-γ+Th1 and IL-17A+ Th17 cell populations, indicating a role in alleviating inflammation via the regulation of Th1/Th17 response [118].